Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation
Rajesh T. Gandhi and colleagues investigate whether elevated immune activation is being driven by or driving HIV persistence. Their findings should inform the design of strategies to reduce HIV persistence and dampen harmful immune activation and inflammation in people who are on long-term treatment.
Image credit: Gandhi RT, et al. (2017)